Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. - Blauvelt A; Papp K; Trivedi M; Barragan C; Chow V; Mytych DT; Yamauchi P; Crowley J; Franklin J (The British journal of dermatology, 2025)